Classificação em ações
#11924
Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the... Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella vaccine; a pneumococcal polysaccharide vaccine designed to prevent Streptococcus pneumoniae infections like pneumonia and septicemia; a quadrivalent influenza vaccine providing defense against two influenza A and two influenza B viruses; and CoronaVac, its vaccine developed to address COVID-19. Additionally, Sinovac's development pipeline features a sabin inactivated polio vaccine, which has concluded Phase III clinical trials for poliomyelitis treatment, alongside a rubella vaccine candidate. The company has established several collaboration agreements, including with GlaxoSmithKline Biologicals SA for the development of measles-containing combination vaccines for the Chinese market; with Tianjin CanSino Biotechnology Inc. to advance a pneumococcal vaccine; and with Instituto Butantan to progress the Phase III clinical trials of CoronaVac, its inactivated COVID-19 vaccine candidate. Sinovac Biotech Ltd. was established in 1993 and maintains its principal offices in Beijing, China.
Preço da ação
$6.47
Última sincronização: 2025-03-10
Valor de mercado
$642.44M
Negociar Sinovac Biotech Ltd. (SVA)
Preço SVA com a capitalização de mercado de B
Capitalização de mercado de Sinovac Biotech Ltd.(SVA)
Valor de mercado: $642.44M
Em August 2026, Sinovac Biotech Ltd. tem uma capitalização de mercado de $642.44M. Isso faz com que Sinovac Biotech Ltd. seja a 11924th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de Sinovac Biotech Ltd. de 2024 a 2026
SVA comparado com o topo de 5 mais populares stocks
| Preço para SVA |
|
Ativo B |
Capitalização de mercado de B |
Resultados |
|
|
|
|
$5.264T
|
+819,259.37%
|
|
|
|
|
$4.701T
|
+731,687.85%
|
|
|
|
|
$4.177T
|
+650,108.15%
|
|
|
|
|
$3.817T
|
+594,106.30%
|
|
|
|
|
$2.866T
|
+446,066.22%
|
